MINJUVI^® PLUS LENALIDOMIDE: CAPTURES THE POTENTIAL FOR ANTI-TUMOUR RESPONSES IN R/R DLBCL, FROM 2L AND BEYOND^1,2

MINJUVI^® (tafasitamab) is a humanised CD19-specific monoclonal antibody, indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

SIGNIFICANT UNMET NEEDS EXIST IN R/R DLBCL

Patients may receive one of multiple treatment options, with generally limited long-term survival^5,6

Many regimens commonly used for R/R DLBCL patients who are transplant ineligible include rituximab, which may not be the most appropriate option for R/R patients, especially those who are CD20-negative^7,8

TREATMENT OPTIONS ARE LIMITED ESPECIALLY FOR R/R DLBCL PATIENTS WHO ARE NON-TRANSPLANT ELIGIBLE

DLBCL is primarily diagnosed in elderly patients who are more likely to have comorbidities, and are diagnosed late via emergency routes in the UK⁹

Many elderly or ‘unfit’ patients are unable or unwilling to receive high-dose chemotherapy¹⁰

There is an urgent need to improve outcomes for patients with DLBCL¹¹

MINJUVI^® PLUS LENALIDOMIDE IN DLBCL: AN INNOVATIVE COMBINATION WITH THE FAMILIARITY OF A MONOCLONAL ANTIBODY (mAb)¹²

CD19 is a proven key target for DLBCL intervention^13,14

MINJUVI^® is a humanised, Fc-enhanced mAb which targets the CD19 antigen expressed on the surface of pre-B and mature B lymphocytes, resulting in malignant B-cell killing activity³

Combining MINJUVI^® plus lenalidomide increases and sustains the benefit of anti-tumour effects versus Minjuvi monotherapy^*1,15

*Based on in vivo, in vitro studies

MINJUVI^® PLUS LENALIDOMIDE: CONSIDER OFFERING YOUR PATIENTS THE POTENTIAL FOR AN ANTI-TUMOUR RESPONSE^1-3,16

MECHANISM OF ACTION

Take advantage of a proven key target for DLBCL intervention

MINJUVI^® SmPC

Local product information

UK Prescribing Information

ROI Prescribing Information

References:

Duell J, et al. Haematologica 2021; 106.
Salles G, et al. Lancet Oncol 2020; 21(7): 978–88.
MINJUVI (tafasitamab) SPC. May 2022. https://www.medicines.org.uk/emc/product/13003/smpc. Last accessed, January 2025.
MINJUVI (tafasitamab) EU SmPC. https://www.ema.europa.eu/en/documents/product-information/minjuvi-epar-product-information_en.pdf. Last accessed, January 2024.
Klink AJ, et al. J Clin Pathways 2020; 6(1): 44–53.
Gisselbrecht C, Van Den Neste E. Br J Haematol 2018; 182: 633–43.
Hiraga J, et al. Blood 2009; 113: 4885–93.
Czuczman MS, et al. Clin Cancer Res 2008; 14: 1561–70.
Smith M, et al. Br J Cancer 2021; 125: 1299–1307.
Di M, Huntington SF, Olszewski AJ. Oncologist 2021; 26(2): 120–132.
Chaganti S, et al. Br J Haematol 2016; 174: 43–56.
Cheson B, et al. Blood Cancer Journal 2021; 11: 68.
Chavez JC, Bachmeier C, Kharfan-Dabaja MA. Ther Adv Hematol 2019; 10: 1–20.
Scheuermann RH & Racila E. Leuk Lymphoma 1995; 18: 385–97.
Burke JM, André M, Cheson BD, et al. Blood 2019; 134 (Suppl 1): 2877.
Witzig TE, Nowakowski GS, Habermann TM, et al. Ann Oncol 2015; 26(8): 1667–77.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events in the UK should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423

Adverse events in ROI should be reported.

Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie

Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800456748

DLBCL, diffuse large B-cell lymphoma; mAb, monoclonal antibody; R/R, relapsed/refractory; SmPC, Summary of Product Characteristics; 2L, second line

EXTERNAL LINK DISCLAIMER

CAUTION

An error occured

MINJUVI® PLUS LENALIDOMIDE: CAPTURES THE POTENTIAL FOR ANTI-TUMOUR RESPONSES IN R/R DLBCL, FROM 2L AND BEYOND1,2

SIGNIFICANT UNMET NEEDS EXIST IN R/R DLBCL

TREATMENT OPTIONS ARE LIMITED ESPECIALLY FOR R/R DLBCL PATIENTS WHO ARE NON-TRANSPLANT ELIGIBLE

There is an urgent need to improve outcomes for patients with DLBCL11

MINJUVI® PLUS LENALIDOMIDE IN DLBCL: AN INNOVATIVE COMBINATION WITH THE FAMILIARITY OF A MONOCLONAL ANTIBODY (mAb)12

Combining MINJUVI® plus lenalidomide increases and sustains the benefit of anti-tumour effects versus Minjuvi monotherapy*1,15

MINJUVI® PLUS LENALIDOMIDE: CONSIDER OFFERING YOUR PATIENTS THE POTENTIAL FOR AN ANTI-TUMOUR RESPONSE1-3,16